Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

BioVentrix Completes Enrollment in Pilot Human Clinical Trial of the PliCath HFâ„¢ Heart Failure Treatment System

November 15, 2011 By AxoGen, Inc.

SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, developer
of the PliCath HF™ System, today announced the achievement of a significant
milestone – completion of enrollment in its pilot human clinical trial. PliCath
HF is a novel device which enables Epicardial Catheter-based Ventricular
Restoration (ECVR). The PliCath HF system is designed to treat the most common
type of heart failure (HF) by restoring a more normal geometry to an enlarged,
scarred heart. This effect is accomplished by exclusion from the left ventricle
(LV) of
non-contracting scar tissue, which typically results from a previous heart
attack. Numerous studies have shown that enlarged hearts not only function
poorly, but also continue to deteriorate, eventually leading to death. PliCath
HF reduces ventricular volume, thus enabling the heart to pump more efficiently
and maintain adequate perfusion to the body without excessive stress on the
muscle of the heart wall.

BioVentrix medical advisor and cardiothoracic surgeon, Dr.
Andrew Wechsler of Drexel
University, participated
in the conduct of the trial and has firsthand experience with the benefits of
the technology. “The PliCath HF device enables significant LV volume reduction, resulting in restoration
of cardiac function without the risk of cutting into the heart or the need for
cardiopulmonary bypass. Most of these patients have attempted other therapies,
were extremely ill, and could not have tolerated a fully invasive surgical
approach requiring entry into the ventricle. These patients have demonstrated
impressive improvement in all categories of assessment. This product has the
potential to benefit a large number of patients with congestive heart failure.”

The 26-patient study was conducted at five leading centers
in Europe, and to date, 12 patients have
reached 90-day follow up or greater. The patients have shown an average indexed
left ventricular end systolic volume (LVESVI) reduction of 31% with a
significant improvement in ejection fraction (the percentage of cardiac volume
ejected with each heart beat). Importantly, these clinical findings were
matched by drastic improvements in the patients functional status and
quality-of-life (QOL) assessments.

HF afflicts a large population, has no cure, and is
progressively disabling. Over a million hospital admissions in the US are due to
HF, resulting in an annual cost of nearly $40 billion. An additional 670,000
new diagnoses and 250,000 HF deaths are estimated each year. Currently,
“open heart procedures” are applied sparingly among such debilitated
patients due to its invasiveness and substantial cost.

“Heart failure remains a problem of epidemic proportions,”
said Kenneth Miller, President & CEO of BioVentrix. “This device will
extend effective treatment to a large group of patients where no other option
is currently available. We are excited to move forward into our next clinical
phase, which will soon include a completely closed chest, minimally invasive
therapy for these patients.”

About BioVentrix

BioVentrix is a private corporation based in San Ramon, California.
Its mission is to improve and expand on the treatment of heart failure,
primarily through the development of less invasive approaches utilizing catheter?based
techniques. BioVentrixs Medical Advisory Board and associated physicians
include some of the worlds leading surgeons and cardiologists. For more
information about the company, please visit www.bioventrix.com.

NOTE: PliCath-HF is an investigational device and is limited
by United States
law to investigational use. For detailed product information, contact David
Schickling, BioVentrix Vice President of Sales and Marketing at (925) 830?1000.

Related Articles Read More >

An illustration of Embolization Inc.'s Nitinol Enhanced Device (NED).
This nitinol vascular embolization device has another shape memory material up its sleeve
A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
July 2025 edition: The Surgical Robotics issue, featuring Capstan Medical, J&J and Zimmer Biomet
A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe